Inflammation in Juvenile Idiopathic Arthritis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 3, 2007, Pages 365-388

  Sullivan, Kathleen E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

B LYMPHOCYTE; BONE EROSION; BONE MARROW CELL; CARTILAGE DEGENERATION; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOID CELL; MACROPHAGE FUNCTION; NEUTROPHIL; OLIGOPHRENIA; PRIORITY JOURNAL; REVIEW; STROMA CELL; SYNOVIOCYTE; T LYMPHOCYTE;

EID: 34948820713     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.07.004     Document Type: Review

References (89)

1. Petty R.E., Southwood T.R., Baum J., et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25 (1998) 1991-1994
2. Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol 22 (2004) 271-275
3. Burgos-Vargas R. Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis 61 Suppl 3 (2002) iii33-iii39
4. Hargreaves K.M., Roszkowski M.T., and Swift J.Q. Bradykinin and inflammatory pain. Agents Actions Suppl 41 (1993) 65-73
5. Kaplan A.P. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation. Fed Proc 42 (1983) 3123-3127
6. Volpe-Junior N., Donadi E.A., Carvalho I.F., et al. Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases. Inflamm Res 45 (1996) 198-202
7. Sambrano G.R., Weiss E.J., Zheng Y.W., et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413 (2001) 74-78
8. Wagner D.D., and Burger P.C. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23 (2003) 2131-2137
9. Paterson N.A., Wasserman S.I., Said J.W., et al. Release of chemical mediators from partially purified human lung mast cells. J Immunol 117 (1976) 1356-1362
10. Dvorak A.M., Schleimer R.P., and Lichtenstein L.M. Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Blood 71 (1988) 76-85
11. Kulas D.T., and Schanberg L. Juvenile idiopathic arthritis. Curr Opin Rheumatol 13 (2001) 392-398
12. Edens H.A., and Parkos C.A. Neutrophil transendothelial migration and alteration in vascular permeability: focus on neutrophil-derived azurocidin. Curr Opin Hematol 10 (2003) 25-30
13. Kruse-Elliott K.T. Pulmonary and neutrophil responses to priming effects of platelet-activating factor in pigs. Am J Vet Res 58 (1997) 1386-1391
14. Schmidt S., Haase G., Csomor E., et al. Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested. J Biomed Mater Res 66A (2003) 491-499
15. Gibbs B.F., Wierecky J., Welker P., et al. Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol 10 (2001) 312-320
16. Mattila P., Majuri M.L., Mattila P.S., et al. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. Scand J Immunol 36 (1992) 159-165
17. MacGregor R.R., Thorner R.E., and Wright D.M. Lidocaine inhibits granulocyte adherence and prevents granulocyte delivery to inflammatory sites. Blood 56 (1980) 203-209
18. Hahnenkamp K., Theilmeier G., Van Aken H.K., et al. The effects of local anesthetics on perioperative coagulation, inflammation, and microcirculation. [see comment]. Anesth Analg 94 (2002) 1441-1447
19. Baerwald C.G., and Panayi G.S. Neurohumoral mechanisms in rheumatoid arthritis. Scand J Rheumatol 26 (1997) 1-3
20. Foell D., Wittkowski H., Hammerschmidt I., et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 50 (2004) 1286-1295
21. Jarvis J.N., Tang Y., Dozmorov I., et al. Gene expression arrays reveal chronic intrinsic activation of neutrophils in children with polyarticular JRA. Is JRA primarily a neutrophil disorder?. [abstract]. Arthritis Rheum 50 Suppl (2004) 1114
22. Silverman E.D., Isacovics B., Petsche D., et al. Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol 91 (1993) 90-95
23. Sediva A., Hoza J., Nemcova D., et al. Immunological investigation in children with juvenile chronic arthritis. Med Sci Monit 7 (2001) 99-104
24. Thompson S.D., Luyrink L.K., Graham T.B., et al. Chemokine receptor CCR4 on CD4 + T cells in juvenile rheumatoid arthritis synovial fluid defines a subset of cells with increased IL-4:IFN-gamma mRNA ratios. J Immunol 166 (2001) 6899-6906
25. Murray K.J., Luyrink L., Grom A.A., et al. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 23 (1996) 2116-2124
26. Wedderburn L.R., Robinson N., Patel A., et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 43 (2000) 765-774
27. Huang J.L., Kuo M.L., Hung I.J., et al. Lowered IL-4-producing T cells and decreased IL-4 secretion in peripheral blood from subjects with juvenile rheumatoid arthritis. Chang Gung Med J 24 (2001) 77-83
28. Shahin A.A., Shaker O.G., Kamal N., et al. Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol Int 22 (2002) 84-88
29. Gregorio A., Gerloni V., Ferlito F., et al. Lymphoid neogenesis in the synovial tissue of patients with JIA. Arthritis Rheum 50 Suppl (2004) 873
30. Blair P.J., Riley J.L., Harlan D.M., et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 191 (2000) 651-660
31. Prahalad S., Ryan M.H., Shear E.S., et al. Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sibpairs. Arthritis Rheum 43 (2000) 2335-2338
32. Moroldo M.B., Donnelly P., Saunders J., et al. Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 41 (1998) 1620-1624
33. Howard J.F., Sigsbee A., and Glass D.N. HLA genetics and inherited predisposition to JRA. J Rheumatol 12 (1985) 7-12
34. Giannini E.H., Malagon C.N., Van Kerckhove C., et al. Longitudinal analysis of HLA associated risks for iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol 18 (1991) 1394-1397
35. Fraser P.A., Stern S., Larson M.G., et al. HLA extended haplotypes in childhood and adult onset HLA-DR4-associated arthropathies. Tissue Antigens 35 (1990) 56-59
36. *0308 in susceptibility to juvenile rheumatoid arthritis. Clin Exp Rheumatol 21 (2003) 399-402
37. Ihle J., Fleckenstein B., Terreaux C., et al. Differential peptide binding motif for three juvenile arthritis associated HLA-DQ molecules. Clin Exp Rheumatol 21 (2003) 257-262
38. Miller M.L., Fraser P.A., Jackson J.M., et al. Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes. Proc Natl Acad Sci U S A 81 (1984) 3539-3542
39. *0101 haplotypes and disease outcome in early onset pauciarticular juvenile rheumatoid arthritis. J Rheumatol 18 (1991) 874-879
40. Glass D.N., and Litvin D.A. Heterogeneity of HLA associations in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 23 (1980) 796-799
41. Miller M.L., Aaron S., Jackson J., et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 28 (1985) 146-150
42. Gallucci S., and Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 13 (2001) 114-119
43. McDevitt H.O. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opin Immunol 10 (1998) 677-681
44. Baum H., Davies H., and Peakman M. Molecular mimicry in the MHC: hidden clues to autoimmunity?. Immunol Today 17 (1996) 64-70
45. Scofield R.H., Warren W.L., Koelsch G., et al. A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. Proc Natl Acad Sci U S A 90 (1993) 9330-9334
46. Colbert R.A. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum?. Mol Med Today 6 (2000) 224-230
47. Gregersen P.K., Silver J., and Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987) 1205-1213
48. McColl G.J., Szer J., Kohaska H., et al. High dose chemotherapy and syngeneic progenitor cell transplantation for severe adult onset Still's disease. Arthritis Rheum 41 (1998) 1703
49. Murray K.J., Grom A.A., Thompson S.D., et al. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25 (1998) 1388-1398
50. Mangge H., and Schauenstein K. Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 10 (1998) 471-480
51. Muzaffer M.A., Dayer J.M., Feldman B.M., et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol 29 (2002) 1071-1078
52. Cook M.C., Basten A., and Fazekas de St Groth B. Rescue of self-reactive B cells by provision of T cell help in vivo. Eur J Immunol 28 (1998) 2549-2558
53. Wu Y., and Liu Y. Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4 + T-cell help in CD8 + T-cell responses. Curr Biol 4 (1994) 499-505
54. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
55. Buckley C.D. Why does chronic inflammatory joint disease persist?. Clin Med 3 (2003) 361-366
56. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
57. Ji H., Ohmura K., Mahmood U., et al. Arthritis critically dependent on innate immune system players. Immunity 16 (2002) 157-168
58. Wouters C.H., Ceuppens J.L., and Stevens E.A. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 20 (2002) 239-248
59. Manners P.J. State of the art: Juvenile idiopathic arthritis. APLAR J Rheumatol 5 (2002) 29-34
60. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14 (2002) 115-120
61. Thomas E., Symmons D.P., Brewster D.H., et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30 (2003) 958-965
62. Watson D.J., Rhodes T., and Guess H.A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30 (2003) 1196-1202
63. Sihvonen S., Korpela M., Mustonen J., et al. Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 96 (2004) c107-c114
64. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
65. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. [see comment]. Lancet 363 (2004) 2015-2021
66. Argyropoulou M.I., Kiortsis D.N., Daskas N., et al. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin Exp Rheumatol 21 (2003) 794-797
67. Huemer M., Fodinger M., Huemer C., et al. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. Clin Exp Rheumatol 21 (2003) 249-255
68. Packham J.C., and Hall M.A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 41 (2002) 1428-1435
69. Lien G., Flato B., Haugen M., et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. [see comment]. Arthritis Rheum 48 (2003) 2214-2223
70. French A.R., Mason T., Nelson A.M., et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol 29 (2002) 1065-1070
71. Kocak I., Yenisey C., Dundar M., et al. Relationship between seminal plasma interleukin-6 and tumor necrosis factor alpha levels with semen parameters in fertile and infertile men. Urol Res 30 (2002) 263-267
72. Naz R.K., Butler A., Witt B.R., et al. Levels of interferon-gamma and tumor necrosis factor-alpha in sera and cervical mucus of fertile and infertile women: implication in infertility. J Reprod Immunol 29 (1995) 105-117
73. Packham J.C., and Hall M.A. Premature ovarian failure in women with juvenile idiopathic arthritis (JIA). Clin Exp Rheumatol 21 (2003) 347-350
74. Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 15 (2003) 581-586
75. Frosch M., Vogl T., Seeliger S., et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48 (2003) 2622-2626
76. Savolainen H.A., and Isomaki H.A. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 20 (1993) 1201-1203
77. Grom A.A. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?. Curr Opin Rheumatol 15 (2003) 587-590
78. Henter J.I. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 38 (2002) 305-309
79. Aggarwal A., and Misra R. Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 23 (2003) 134-137
80. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003) 1093-1101
81. Yokota S., Imagawa T., Miyamae T., et al. Long-term therapeutic experience of humanized anti-IL-6 monoclonal antibody in systemic onset juvenile idiopathic arthritis. [abstract]. Arthritis Rheum 50 Suppl (2004) 1100
82. Dekker L., Armbrust W., Rademaker C.M., et al. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 22 (2004) 252-258
83. Nielsen O.H., Bukhave K., Elmgreen J., et al. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 32 (1987) 577-582
84. Bissonnette E.Y., Enciso J.A., and Befus A.D. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol 156 (1996) 218-223
85. Lovell D.J., Giannini E.H., Reiff A., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48 (2003) 218-226
86. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342 (2000) 763-769
87. Isomaki P., Panesar M., Annenkov A., et al. Prolonged exposure of T cells to TNF down-regulates TCRzeta and expression of the TCR/CD3 complex at the cell surface. J Immunol 166 (2001) 5495-5507
88. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 (2002) 3151-3158
89. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Group B: treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127